SpecC1L-ADORA2A: A Potent Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: SPECC1L-ADORA2A

NCBI ID: G101730217

SPECC1L-ADORA2A

Other Name(s): SPECC1L-ADORA2A readthrough (NMD candidate)

SpecC1L-ADORA2A: A Potent Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, primarily as a result of the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. The most common cause of Alzheimer's disease is the neurodegeneration theory, which suggests that the build-up of these aggregates of misfolded proteins is the primary cause of the disease. Although there is no cure for Alzheimer's disease, the development of new therapeutics that can slow down or halt the progression of the disease is a promising approach to managing the condition.

SpecC1L-ADORA2A: A novel drug target and biomarker for Alzheimer's disease

SpecC1L-ADORA2A is a novel drug target and biomarker that has been identified as a potential therapeutic intervention for Alzheimer's disease. This protein is expressed in the brain and has been shown to be involved in the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease. By blocking the activity of SpecC1L-ADORA2A, researchers have found that they can reduce the formation of beta-amyloid plaques and improve cognitive function in animal models of Alzheimer's disease.

The search for new treatments for Alzheimer's disease has led to the development of a wide range of therapeutic approaches, including drugs that target the production, processing, or storage of beta-amyloid plaques. However, these approaches have been largely limited by their ability to cross the blood-brain barrier and their potential side effects. By using SpecC1L-ADORA2A as a drug target, researchers have identified a new way to interfere with the formation of beta-amyloid plaques and may have identified a potential therapeutic approach for Alzheimer's disease.

SpecC1L-ADORA2A is a member of the ADORA2 family, which includes several proteins that have been shown to be involved in the formation of beta-amyloid plaques. The ADORA2 family is characterized by the presence of a unique N-terminal region that consists of a long coiled-coil and a C-terminal region that contains a protein-coding domain. The N-terminal region is known as the N-terminal transmembrane domain (N-TMD) and is thought to play a role in the formation of beta-amyloid plaques by interacting with the brain environment.

SpecC1L-ADORA2A is expressed in the brain and has been shown to be involved in the formation of beta-amyloid plaques in animal models of Alzheimer's disease. By using antibodies to block the activity of SpecC1L-ADORA2A, researchers have found that they can reduce the formation of beta-amyloid plaques and improve cognitive function in animal models of Alzheimer's disease. These results are consistent with previous studies that have shown that SpecC1L-ADORA2A is involved in the formation of beta-amyloid plaques and that blocking its activity may be a promising therapeutic approach for Alzheimer's disease.

In addition to its potential as a therapeutic intervention, SpecC1L-ADORA2A is also a promising biomarker for Alzheimer's disease. The accumulation of beta-amyloid plaques is a well-established biomarker for Alzheimer's disease, and the formation of these plaques can be detected in brain tissue from individuals with Alzheimer's disease. By using SpecC1L-ADORA2A as a drug target and biomarker, researchers have identified a new way to diagnose and

Protein Name: SPECC1L-ADORA2A Readthrough (NMD Candidate)

The "SPECC1L-ADORA2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPECC1L-ADORA2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets